IR@PKUHSC  > 北京大学药学院  > 药剂学系
学科主题药学
Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies
Zhang, Yi-fei2; Wang, Jian-cheng1,2; Bian, Dong-yan2,3; Zhang, Xuan2; Zhang, Qiang1,2
关键词Combination Therapy Liposomes Targeting Combretastatin A-4 Doxorubicin
刊名EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
2010-03-01
DOI10.1016/j.ejpb.2010.01.002
74期:3页:467-473
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]ANTITUMOR EFFICACY ; CELLS ; CHEMOTHERAPY ; PHOSPHATE ; AGENTS ; DRUGS ; ANGIOGENESIS ; VASCULATURE ; COMBINATION ; INDUCTION
英文摘要

Arg-Gly-Asp (RGD) modified doxorubicin-loaded liposomes could Improve anticancer effect, and vascular disrupting agents (VDAs) could induce a rapid and selective shutdown of the blood vessels of tumors We propose that RGD-modified liposomes for co-encapsulation and sequential release of vascular disrupting agent combretastatin A-4 (CA-4) and cytotoxic agent doxorubicin (Dox) could enhance tumor inhibition responses In this study, we encapsulated Dox and CA-4 in RGD-modified liposomes The release are of Dox was proved to be much slower than that of CA-4 in vitro Flow cytometry and laser confocal scanning microscopy clearly showed that RGD-modification promoted intracellular uptake of liposomal drugs by B16/B16F10 melanoma tumor cells and human umbilical vein endothelial cells (HUVECs) Cytotoxicity assay showed that the IC(50) of RGD-modified liposomes was lower than that of the corresponding unmodified liposomes Therapeutic benefits were examined on B16F10 melanoma tumors subcutaneously glowing in C57BL/6 mice In vivo study demonstrated that RGD-modified liposomes exhibited the most pronounced tumor regression effect when both CA-4 and Dox were co-encapsulated These results suggest that the targeted drug delivery system for co-encapsulation of vascular disrupting agents and anticancer agents may be a promising strategy for cancer treatment (c) 2010 Elsevier B.V All rights reserved

语种英语
WOS记录号WOS:000276426200007
项目编号2007AA021811 ; 200703935800 ; 2009z09310-001
资助机构National High Technology Research and Development Program of China ; National Basic Research Program of China ; National Key Program of New Drug innovation
引用统计
被引频次:91[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53617
专题北京大学药学院_药剂学系
北京大学口腔医学院_中心实验室
作者单位1.Peking Univ, Dept Pharmaceut, Sch Pharmaceut Sci, Beijing 100083, Peoples R China
2.Peking Univ, Hlth Sci Ctr, State Key Lab Nat & Bromimet Drugs, Beijing 100083, Peoples R China
3.Shen Yang Pharmaceut Univ, Dept Pharmaceut, Shenyang, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Yi-fei,Wang, Jian-cheng,Bian, Dong-yan,et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies[J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS,2010,74(3):467-473.
APA Zhang, Yi-fei,Wang, Jian-cheng,Bian, Dong-yan,Zhang, Xuan,&Zhang, Qiang.(2010).Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies.EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS,74(3),467-473.
MLA Zhang, Yi-fei,et al."Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies".EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 74.3(2010):467-473.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Yi-fei]的文章
[Wang, Jian-cheng]的文章
[Bian, Dong-yan]的文章
百度学术
百度学术中相似的文章
[Zhang, Yi-fei]的文章
[Wang, Jian-cheng]的文章
[Bian, Dong-yan]的文章
必应学术
必应学术中相似的文章
[Zhang, Yi-fei]的文章
[Wang, Jian-cheng]的文章
[Bian, Dong-yan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。